752 related articles for article (PubMed ID: 32122777)
1. Racial Disparity in the Prescription of Anticoagulants and Risk of Stroke and Bleeding in Atrial Fibrillation Patients.
Tedla YG; Schwartz SM; Silberman P; Greenland P; Passman RS
J Stroke Cerebrovasc Dis; 2020 May; 29(5):104718. PubMed ID: 32122777
[TBL] [Abstract][Full Text] [Related]
2. Use of oral anticoagulation therapy in the first 3 months after the diagnosis of atrial fibrillation in Israel: A population-based study.
Kezerle L; Tsadok MA; Berliner Senderey A; Hoshen M; Leventer-Roberts M; Reges O; Leibowitz M; Haim M
J Cardiovasc Electrophysiol; 2020 Jun; 31(6):1356-1363. PubMed ID: 32212197
[TBL] [Abstract][Full Text] [Related]
3. Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends.
Shiyovich A; Shalev V; Chodick G; Tirosh M; Katz A; Klar MM; Shuvy M; Pereg D; Minha S
BMC Cardiovasc Disord; 2021 Oct; 21(1):493. PubMed ID: 34645389
[TBL] [Abstract][Full Text] [Related]
4. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
[TBL] [Abstract][Full Text] [Related]
5. Stroke-prevention strategies in North American patients with atrial fibrillation: The GLORIA-AF registry program.
McIntyre WF; Conen D; Olshansky B; Halperin JL; Hayek E; Huisman MV; Lip GYH; Lu S; Healey JS
Clin Cardiol; 2018 Jun; 41(6):744-751. PubMed ID: 29546729
[TBL] [Abstract][Full Text] [Related]
6. Flaws in Anticoagulation Strategies in Patients With Atrial Fibrillation at Hospital Discharge.
Kartas A; Samaras A; Vasdeki D; Dividis G; Fotos G; Paschou E; Forozidou E; Tsoukra P; Kotsi E; Goulas I; Efthimiadis G; Karvounis H; Tzikas A; Giannakoulas G
J Cardiovasc Pharmacol Ther; 2019 May; 24(3):225-232. PubMed ID: 30599759
[TBL] [Abstract][Full Text] [Related]
7. Prescription Patterns and Outcomes of Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis.
Kattoor AJ; Pothineni NV; Goel A; Syed M; Syed S; Paydak H; Mehta JL
J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):428-434. PubMed ID: 31035795
[TBL] [Abstract][Full Text] [Related]
8. Prescription patterns of oral anticoagulants for patients with non-valvular atrial fibrillation: experience at a Japanese single institution.
Tagaya M; Yoshikawa D; Sugishita Y; Yamauchi F; Ito T; Kamada T; Yoshinaga M; Mukaide D; Fujiwara W; Yokoi H; Hayashi M; Watanabe E; Ishii J; Ozaki Y; Izawa H
Heart Vessels; 2016 Jun; 31(6):957-62. PubMed ID: 26022376
[TBL] [Abstract][Full Text] [Related]
9. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study.
Martinez C; Katholing A; Wallenhorst C; Freedman SB
Thromb Haemost; 2016 Jan; 115(1):31-9. PubMed ID: 26246112
[TBL] [Abstract][Full Text] [Related]
10. Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk.
Potpara TS; Lip GY
Prog Cardiovasc Dis; 2015; 58(2):177-94. PubMed ID: 26162958
[TBL] [Abstract][Full Text] [Related]
11. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
[TBL] [Abstract][Full Text] [Related]
12. Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II).
Steinberg BA; Shrader P; Pieper K; Thomas L; Allen LA; Ansell J; Chan PS; Ezekowitz MD; Fonarow GC; Freeman JV; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli GV; Reiffel JA; Singer DE; Peterson ED; Piccini JP;
J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29453305
[TBL] [Abstract][Full Text] [Related]
13. Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study.
Gieling EM; van den Ham HA; van Onzenoort H; Bos J; Kramers C; de Boer A; de Vries F; Burden AM
Br J Clin Pharmacol; 2017 Aug; 83(8):1844-1859. PubMed ID: 28205318
[TBL] [Abstract][Full Text] [Related]
14. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral anticoagulants: a nationwide cohort study.
Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Yeh YH; Kuo CT; See LC; Lip GYH
Eur Heart J Cardiovasc Pharmacother; 2023 Dec; 9(8):681-691. PubMed ID: 37580139
[TBL] [Abstract][Full Text] [Related]
16. Temporal Trends in Pharmacological Stroke Prevention in Patients with Acute Ischemic Stroke and Known Atrial Fibrillation.
Hellwig S; Grittner U; Herm J; Ruschmann R; Konieczny M; Endres M; Haeusler KG
J Stroke Cerebrovasc Dis; 2020 Dec; 29(12):105266. PubMed ID: 32992191
[TBL] [Abstract][Full Text] [Related]
17. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage.
Tsai CT; Liao JN; Chiang CE; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chao TF; Lip GYH; Chen SA
JAMA Netw Open; 2020 Jun; 3(6):e206424. PubMed ID: 32478848
[TBL] [Abstract][Full Text] [Related]
18. Reasons for and consequences of oral anticoagulant underuse in atrial fibrillation with heart failure.
Savarese G; Sartipy U; Friberg L; Dahlström U; Lund LH
Heart; 2018 Jul; 104(13):1093-1100. PubMed ID: 29371374
[TBL] [Abstract][Full Text] [Related]
19. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
[TBL] [Abstract][Full Text] [Related]
20. Race/Ethnicity and Sex-Related Differences in Direct Oral Anticoagulant Initiation in Newly Diagnosed Atrial Fibrillation: A Retrospective Study of Medicare Data.
Essien UR; Magnani JW; Chen N; Gellad WF; Fine MJ; Hernandez I
J Natl Med Assoc; 2020 Feb; 112(1):103-108. PubMed ID: 32035755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]